Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cutting Edge Information
Market research firm releases new report on oncology brand commercialization
October 26th, 2005
Commercialization resource levels for follow-on oncology drugs surpass newly developed, first-to-market drugs, according to a report by pharmaceutical research firm Cutting Edge Information. First-to-market drugs mold entirely new markets, and brand teams concentrate marketing budgets on promoting their drug's benefits rather than on winning out the competition. Unlike follow-on drugs that focus on gaining market share, first-to-market drugs take advantage of the lack of competition at launch and disburse about $31.5 million less overall than follow-on drugs. Overall, follow-on drugs expend about 51% more at launch than first-to- market drugs. The...
Source: Elder Law Weekly (2005-10-26)
|
